New 'Living Drug' trial aims to calm immune attacks after transplants
NCT ID NCT05993611
Summary
This is a first-in-human study to test the safety and best dose of a new cell therapy for patients with chronic graft-versus-host disease (cGVHD). cGVHD is a serious condition where the immune cells from a donor transplant attack the patient's own body. The therapy involves giving patients specially engineered 'regulatory' immune cells designed to calm this harmful immune attack and promote long-term disease control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.